Low‐dose vemurafenib in hairy cell leukemia patients with active infection

REFERENCES 1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5): 496-509. 2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. 3. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74(4):459-469. 4. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. 5. Li X, Li J, Wang L, et al. Transmission of psoriasis by allogeneic bone marrow transplantation and blood transfusion. Blood Cancer J. 2015;5 (3):e288. 6. Kanamori H, Tanaka M, Kawaguchi H, et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol. 2002;71(1):41-44. 7. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35 (11):1154-1161. 8. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.

• Publication year

  2019

• Venue

  American journal of hematology/oncology

• Publication date

  2019-04-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.25474PMID 30916799PMCID 6593695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

  2017cited by this paper
• Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

  2017cited by this paper
• Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

  2015cited by this paper
• The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

  2011cited by this paper
• Long-term results for pentostatin and cladribine treatment of hairy cell leukemia

  2011cited by this paper
• Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.

  2003cited by this paper

• Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbidities.

  2025cites this paper
• Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types

  2025cites this paper
• Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia

  2025cites this paper
• Concomitantly Diagnosed Disseminated M kansasii Infection and Hairy Cell Leukemia With Review of Pathophysiology

  2024cites this paper
• Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies

  2024cites this paper
• Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.

  2024cites this paper
• Hairy-Cell Leukemia.

  2024cites this paper
• Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group

  2024cites this paper
• A hajas sejtes leukémia és kezelése

  2023cites this paper
• Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

  2023cites this paper
• Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials

  2023cites this paper
• Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances

  2022cites this paper
• How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

  2022cites this paper
• Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine

  2022cites this paper
• Hairy Cell Leukemia Patients Have a Normal Life Expectancy—A 35-Year Single-Center Experience and Comparison with the General Population

  2022cites this paper
• Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib

  2022cites this paper
• Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.

  2022cites this paper
• Experience with the Use of B-RAF Inhibitor Vemurafenib in the Treatment of Hairy Cell Leukemia

  2022cites this paper
• Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders

  2022cites this paper
• A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A

  2022cites this paper
• Leucémie à tricholeucocytes et autres proliférations à cellules chevelues

  2022cites this paper
• Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.

  2021cites this paper
• Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications.

  2021cites this paper
• Hairy cell leukemia: a brief update on current knowledge and treatment prospects

  2021influential citation
• Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment

  2021cites this paper
• Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox

  2021cites this paper
• The Biology of Classic Hairy Cell Leukemia

  2021cites this paper
• Targeted therapy for treatment of patients with classical hairy cell leukemia.

  2021cites this paper
• Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

  2021cites this paper
• Biology and Treatment of Hairy Cell Leukemia

  2020cites this paper
• Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia.

  2020cites this paper
• The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant

  2020cites this paper
• Cladribine/pentostatin/rituximab

  2019cites this paper
• BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials

  2019cites this paper
• Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.

  2019cites this paper